Format

Send to

Choose Destination
Expert Opin Ther Targets. 2012 Dec;16(12):1161-74. doi: 10.1517/14728222.2012.726985. Epub 2012 Sep 24.

Therapeutic targeting of the p53 pathway in cancer stem cells.

Author information

1
Penn State Hershey Cancer Institute, Penn State College of Medicine, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), 500 University Drive, Room T4423, Hershey, PA 17033, USA.

Abstract

INTRODUCTION:

Cancer stem cells (CSCs) are a high profile drug target for cancer therapeutics due to their indispensable role in cancer progression, maintenance and therapeutic resistance. Restoring wild-type (WT) p53 function is an attractive new therapeutic approach for the treatment of cancer due to the well-described powerful tumor suppressor function of p53. As emerging evidence intimately links p53 and stem cell biology, this approach also provides an opportunity to target CSCs.

AREAS COVERED:

This review covers the therapeutic approaches to restore the function of WT p53, cancer and normal stem cell biology in relation to p53 and the downstream effects of p53 on CSCs.

EXPERT OPINION:

The restoration of WT p53 function by targeting p53 directly, its interacting proteins or its family members holds promise as a new class of cancer therapies. This review examines the impact that such therapies may have on normal and CSCs based on the current evidence linking p53 signaling with these populations.

PMID:
22998602
PMCID:
PMC3650610
DOI:
10.1517/14728222.2012.726985
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center